21 results on '"Ribaudo, Heather J"'
Search Results
2. Ideal cardiovascular health, biomarkers, and coronary artery disease in persons with HIV.
3. Diet in a global cohort of adults with HIV at low-to-moderate traditional cardiovascular disease risk.
4. Prevalence and Correlates of Electrocardiographic Abnormalities in Adults With HIV: Insights From the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).
5. Methotrexate Decreases Tenofovir Exposure in Antiretroviral-Suppressed Individuals Living With HIV.
6. The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial.
7. Racial differences in calculated bioavailable vitamin D with vitamin D/calcium supplementation.
8. Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir.
9. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness.
10. Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.
11. Body Composition, Soluble Markers of Inflammation, and Bone Mineral Density in Antiretroviral Therapy-Naive HIV-1-Infected Individuals.
12. Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection.
13. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.
14. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure.
15. Comparative Effectiveness of Initial Antiretroviral Therapy Regimens.
16. Racial Differences in Virologic Failure Associated With Adherence and Quality of Life on Efavirenz-Containing Regimens for Initial HIV Therapy Results of ACTG A5095.
17. Metabolic Effects of Protease Inhibitor—Sparing Anti retroviral Regimens Given as InitialTreatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).
18. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.
19. Hepatic steatosis and nonalcoholic fatty liver disease are common and associated with cardiometabolic risk in a primary prevention cohort of people with HIV.
20. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
21. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.